Clinuvel Pharmaceuticals Limited (ASX:CUV) is a global biopharmaceuticals company with a focus on developing and delivering treatments for patients with a range of severe genetic and skin disorders. Clinuvel’s main product is called SCENESSE, which it develops and self-distributes.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.51% to 6925.50.
Shares in Clinuvel Pharmaceuticals Limited (ASX:CUV) were down as much as 21% today to be one of the worst performers on the ASX 200.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.03% at lunch.
The Clinuvel Pharmaceuticals Limited (ASX:CUV) and Harvey Norman Holdings Limited (ASX:HVN) share prices are down, here’s why.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.77% at lunch.
Shares in Clinuvel Pharmaceuticals Limited (ASX:CUV) opened more than 40% higher this morning after receiving FDA approval for its marquee product SCENESSE.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.50% at lunch.
Clinuvel Pharmaceuticals Limited (ASX:CUV) shares opened more than 3% higher this morning after announcing a renewed employment agreement with the existing CEO. Here’s what you need to know.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.52% at lunch.
